What is Cosmo Pharmaceuticals NV Enterprise Value?
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Cosmo Pharmaceuticals NV's Enterprise Value is CHF1,103.4 Mil.
Cosmo Pharmaceuticals NV's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was CHF27.7 Mil. Therefore, Cosmo Pharmaceuticals NV's EV-to-EBIT ratio for today is 39.83.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Cosmo Pharmaceuticals NV's Enterprise Value
For the Drug Manufacturers - General subindustry, Cosmo Pharmaceuticals NV's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cosmo Pharmaceuticals NV's Enterprise Value Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cosmo Pharmaceuticals NV's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Cosmo Pharmaceuticals NV's Enterprise Value falls into.
Cosmo Pharmaceuticals NV Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Cosmo Pharmaceuticals NV's Enterprise Value for the fiscal year that ended in Dec. 2022 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cosmo Pharmaceuticals NV (XSWX:COPN) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Cosmo Pharmaceuticals NV's EV-to-EBIT for today is
Cosmo Pharmaceuticals NV's current Enterprise Value is CHF1,103.4 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Cosmo Pharmaceuticals NV's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was CHF27.7 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Cosmo Pharmaceuticals NV's EV-to-EBITDA for today is:
Cosmo Pharmaceuticals NV's current Enterprise Value is CHF1,103.4 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Cosmo Pharmaceuticals NV's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 was CHF41.4 Mil.
Cosmo Pharmaceuticals NV's current Enterprise Value is CHF1,103.4 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Cosmo Pharmaceuticals NV's Revenue for the trailing twelve months (TTM) ended in Jun. 2023 was CHF102.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cosmo Pharmaceuticals NV Enterprise Value Related Terms
Thank you for viewing the detailed overview of Cosmo Pharmaceuticals NV's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Cosmo Pharmaceuticals NV (XSWX:COPN) Business Description
Cosmo Pharmaceuticals NV is a pharmaceutical company with a focus on gastrointestinal diseases, dermatology and healthtech. The company develops and manufactures products that are distributed globally by its partners. Products that the company has developed include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo for the treatment of travellers' diarrhoea (TD) and Winlevi for the treatment of acne. Product pipeline includes Breezula, GI Genius, Methylene blue MMX, Aemcolo, CB-03-10 and CB-01-33.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XSWX:COPN has been successfully added to your 